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Abstract 
Maternal hypertiroidism is a relative rare disorder, which can seriously complicate pregnancy in each of its 
periods. There are several maternal and fetal complications during pregnancy, delivery and postpartum period. Correct 
management  includes  an  accurate  diagnosis,  rigorous  individualized  treatment  and  minutious  follow-up.  We  are 
presenting a retrospective study of 38 pregnant women who delivered in the Obstetric Unit of the University Emergency 
Bucharest Hospital in the past five years. We established a follow-up protocol in collaboration with endocrinologists. 
Precocious diagnosis of pregnancy is, in our opinion, mandatory. Accurate diagnosis of hormonal status beginning from 
the first week of pregnancy is of great importance. Maternal (weight, BP, TSH, thyroid hormones, ECG, etc.) and fetal 
(ultrasound, non-stress test, Doppler study) evaluation during pregnancy were rigorous performed. Results: abortion 
rate  was  5%;  15%  of  pregnant  women  delivered  prematurely;  cesarean  section  rate  was  22%;  fetal  outcome  was 
excellent. Treatment adjustment during pregnancy was frequent, 28% of pregnant women had no hormonal treatment in 
the last trimester of pregnancy. Maternal complications were rare (poor weight gain, tachycardia). Fetal complications 
included  low  birth  weight  (24%),  fetal  respiratory  distress  (10%).  Conclusions:  team  work  with  experienced 
endocrinologists and understanding of versatility of disease leads to good prognosis of mother and fetus in presence of 
hypertiroidism.    
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Introduction 
 
Maternal  hyperthyroidism  is  a  relative  rare  disorder,  which  can  seriously  complicate 
pregnancy in each of its periods. The most common cause of hyperthyroidism during pregnancy is 
Graves’  disease  [1].  Graves’  disease  is  a  complex  autoimmune  disorder,  characterized  by 
autoantibodies  that  activate  the  TSH  receptor.  These autoantibodies  cross  the  placenta and  can 
cause  fetal  and  neonatal  thyroid  dysfunction  even  when  the  mother  herself  is  in  an  euthyroid 
condition.  Exceptional,  hyperthyroidism  in  pregnancy  has  a  different  cause  other  than  Graves’ 
disease  like  hyperemesis  gravidarum,  gestational  transient  hyperthyroidism,  hydatiform  mola, 
choriocarcinoma [1, 2]. 
 
Clinical consideration and diagnosis 
 
The  signs  and  symptoms  of  hyperthyroidism  can  include  tachycardia,  palpitations,  heat 
intolerance, nervousness, goiter, weight loss, thyromegaly, exophthalmia, increased appetite, nausea 
and vomiting, sweating, and tremor.
 Many of these symptoms are also seen in pregnant women who 
have normal thyroid function. The most discriminatory features of hyperthyroidism in pregnancy 
are persistent tachycardia, weight loss, systolic flow murmurs, tremor, lid lag and exophthalmia. 
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Most  pregnant  women  with  hyperthyroidism  have  already  been  diagnosed  prior  to 
pregnancy.  
The diagnosis of overt hyperthyroidism rests on laboratory tests, particularly on the estimation of 
suppressed serum TSH. There are also elevated levels of free thyroxin (FT4) and free triiodothyronine 
(FT3). Subclinical hyperthyroidism is defined as a suppressed TSH level with normal FT 4 and FT3 levels. 
A form of hyperthyroidism called the T3– toxicosis syndrome is diagnosed by suppressed TSH, normal 
FT4, and elevated FT3 levels [2, 3].  
Pregnant women tolerate mild to moderate degrees of hyperthyroidism relatively well. If the 
diagnosis is in doubt, the thyroid function tests can be repeated in 3 or 4 weeks before making a final 
decision. 
Graves’  disease,  being  an  autoimmune  disease,  may  be  exacerbated  in  the  early  parts  of 
pregnancy, but as immune suppression typically occurs with the pregnancy, Graves’ disease improves. 
Postpartum, the patient may remain in a permanent remission, but recurrence is also possible. 
 
Measurement of antibodies 
 
Antithyroid antibodies are common in patients with autoimmune thyroid disease, as a response to 
thyroid antigens. The two most common antithyroid antibodies are thyroglobulin and thyroid peroxidase 
(anti-TPO).  Anti-TPO  antibodies  are  associated  with  postpartum  thyroiditis  and  fetal  and  neonatal 
hyperthyroidism  [4].  TSH-receptor  antibodies  include  thyroid-stimulating  immunoglobulin  (TSI)  and 
TSH-receptor antibody. TSI is associated with Graves’ disease. TSH-receptor antibody is associated with 
fetal goiter, congenital hypothyroidism, and chronic thyroiditis without goiter. 
Recent studies investigated the relationship between the presence of antithyroid antibodies and 
pregnancy  complications,  finding  a  high  proportion  of  women  with  previous  history  of  obstetric 
complications and high levels of circulating anti-thyroid peroxidase antibodies and anti-thyroglobulin 
antibodies. Furthermore, thyroid function disorders may affect the course of pregnancy [5].   
Antibody patterns generally fluctuate with pregnancy, reflecting the clinical progress of the disease, 
but may remain stable in patients with low antibody titers [6]. TRAbs can be detected in the first trimester, 
but values often decrease during the second and third trimesters and might become undetectable before 
increasing again postpartum [5, 6]. Clinically, patients can experience relapse or worsening of Graves' 
disease by 10-15 weeks of gestation. Graves' disease can, however, remit late in the second and third 
trimesters. 
The antibodies should be measured in the following situations: 
  Women with Graves’ disease who had fetal or neonatal hyperthyroidism in a previous 
pregnancy 
  Women with Graves’ disease who receive antithyroid drugs 
  Euthyroid pregnant woman with fetal tachycardia or intrauterine growth restriction 
  Presence of fetal goiter on ultrasound. 
 
Maternal-fetal complications 
 
Hyperthyroidism can have multiple effects on the pregnant woman and her fetus, varying in 
severity from the minimal to the catastrophic. 
If left untreated, and it should not be left untreated, it is possible to have hypertension, congestive 
heart failure, thyroid storm with labor, increased abortion rate, premature labor, stillbirth or neonatal death, 
low birth weight baby, fetal abnormalities.  Journal of Medicine and Life Vol. 1, No.4, October-December 2008 
  392 
 
Material and methods 
 
We performed a retrospective study of 38 pregnant women, who were treated and delivered in our 
clinic  in  the  past  five  years.  The  most  common  cause  of  hyperthyroidism  was Graves’  disease  (34 
patients). Other causes were hyperemesis gravidarum and gestational transient hyperthyroidism.  
The most common clinical signs were: palpitations, tachycardia, heat intolerance and emotional 
liability. Discriminatory features  were persistent tachycardia,  weight loss,  systolic flow  murmur, and 
tremor. 
Together with endocrinologists, we established a follow-up protocol. Accurate and precocious 
diagnostic of hormonal status beginning from the first weeks of pregnancy is of great importance. 
Our  protocol  included  preconceptional  counseling,  antenatal,  intrapartum  and  postnatal 
management, with careful maternal and fetal evaluation [7]. 
 
Preconceptional counseling 
Preconceptional advice is very important. We believe that counseling about the effects of the disease 
on maternal health and on fetal well-being remove anxiety commonly present among these women. The 
patient’s thyroid status should be checked frequently to minimize risk of miscarriage  [8]. 
We informed the patients that discontinuing the treatment would lead to a higher risk of mortality and 
morbidity  to  both  the  mother  and  her  fetus.  In  2  cases,  where  the  treatment  was  initiated  with 
methimazole, we changed to propylthiouracil and we ensured the patients that the medication is not 
teratogenic and safe to be used in pregnancy [7, 8]. 
 
Antenatal and intrapartum management - previously treated patients with Grave’s disease 
In our group, 20 patients received antithyroid drugs and 4 of them underwent surgery. The important 
concern here is that fetal and neonatal hyperthyroidism may still occur. 
According to recent guidelines, the measurement of the TSH receptor antibodies is not required, if 
antithyroid drugs have been used because the maternal thyroid function provides a reliable estimate of 
fetal thyroid status and the risk of neonatal hyperthyroidism is very low. 
The TSH receptor antibodies will be measured in an euthyroid pregnant woman previously treated by 
radioiodine therapy or surgical. If the level is high, the fetus should be carefully assessed during gestation 
and the antibodies measured again in the last trimester [9]. 
 
Patient status  Antibodies measurement  
Euthyroid – previous antithyroid drugs   Not necessary  
Euthyroid ± T4 therapy 
Previous radioiodine therapy/surgery  
Check in early pregnancy: 
–   if low or absent no further testing 
–   if  high:  check  fetus  and  check 
antibodies in last trimester  
Receiving  antithyroid  drugs  during 
pregnancy 
Measure in last trimester 
 
Tabel 1. Guidelines for measurements of TSH – receptor antibodies in a pregnant woman with  
Grave’s disease (9) 
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In our series, the antibodies in women who underwent surgery were very low [7]. 
 
 Antenatal and intrapartum management - patients found to have Grave's disease in early 
pregnancy 
 
We  preferred  medical  therapy  as  radioiodine  is  contraindicated  and  surgery  requires 
pretreatment with antithyroid drugs to render the patient euthyroid. 
Thioamide drug therapy (propylthiouracil, methimazole, carbimazole) is the first line therapy, 
indicated for moderate or severe hyperthyroidism.  
The drug of choice is propylthiouracil, given in a dose of 100 – 150 mg three times daily until 
the patient becomes euthyroid (with normal thyroid function tests) at which time the dose should be 
reduced to the lowest amount to maintain the euthyroid state. 
Although there have been no prospective clinical trials, multiple case reports have associated 
methimazole with two types of fetal abnormalities: choanal or esophageal atresia and aplasia cutis 
[10]. 
 
Beta-blockers are relatively contraindicated, but not absolutely, so that propranolol can be used 
until T4 levels normalized. 
The complications of the drugs include: 
-  Lower Apgar scores 
-  Intrauterine growth retardation 
-  Postnatal bradycardia, hypothermia and hypoglycemia 
-  Neonatal respiratory distress [9, 10]. 
 
Our series is characterized by a multidisciplinary effort between family physician, obstetrician 
and endocrinologist, in order to achieve optimal control of hyperthyroidism. 
Most of the patients (82%) received medical therapy, based on thioamides as first line therapy 
and propranolol in 2 cases. The use of propranolol was associated with releasing of sympathetic 
symptoms like tachycardia, tremor and sweating. We used a dose of 30 mg for short periods and 
after that we reduced it gradually. 
28% of patients had no hormonal treatment in the last trimester of pregnancy, being very careful 
followed-up. 
Intrapartum, we maintained the lowest dose of medication.  
Vaginal  delivery  was  the  mode  of  choice  (70%)  and  caesarean  section  was  reserved  for 
obstetrical indication (22%). 
We present the algorithm we used in our clinic (Fig.1) [7]. 
After an accurate and as possible precocious diagnosis, we started antithyroid drugs, until the 
patient became euthiroid. We continued with the lowest dose of antithyroid drugs up and during 
labor. 
The thyroid function was monitored every 4 weeks; with adjust of medication, when necessary. 
We checked the antibodies in the third trimester, at 36 weeks. 
Counseling of the patient was also important; we discussed the maternal-fetal and breastfeeding 
effects of the treatment. 
It is also important to check the infants for possible thyroid dysfunction. 
We reviewed the patients postpartum for exacerbation. 
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Fig.  1. Management of hyperthyroidism in pregnancy (7) 
 
Postpartum management 
During the postpartum period, the mother should be encouraged to breastfeed her baby, as the 
excretion in the milk of antithyroid drugs is very low. It is therefore safe to continue treatment and 
breastfeeding, provided not exceeding the doses [11 – 13]. 
Radioiodine therapy is contraindicated in pregnancy and breastfeeding, since it is taken up by 
the fetal/newborn thyroid and may result in thyroid ablation and hypothyroidism. 
 
Maternal evaluation 
 
We evaluated the pregnant women by monitoring  
-  The weight: either weight loss (2 cases), or poor weight gain (5 -8 kg) 
-  Persistent tachycardia was observed in 24 cases 
-  We also tested the levels of thyroid hormones and the levels of antibodies 
-  The blood pressure was normal in most of the cases 
 
Confirm diagnosis 
Propylthiouracil 100-150mgx3/day  
 
Euthyroid status 
 
Low dose ATD up and during labor 
Monitor thyroid function 
(4 weekly) 
Adjust ATD if necessary 
TSH receptor 
antibodies at 36 
weeks  
 
Discuss treatment: 
maternal-fetal and 
breastfeeding effects 
 
Check the infant 
for thyroid 
dysfunction 
Review postpartum – check for exacerbation  
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Fetal evaluation 
 
The fetus is at risk of thyroid dysfunction if the mother has TSH receptor antibodies and/or 
is taking anti-thyroid drugs during the third trimester. 
Fetal  evaluation  (non  stress  test  and  ultrasound)  was  precisely  performed  and  the  fetal 
outcome was excellent.  
We performed serial ultrasound, before 28 and 32 weeks of gestation. 
Fetal thyroid gland monitoring by ultrasonography is very important [14]. Demonstration of 
fetal goiter by ultrasonography is an important predictor of fetal thyroid dysfunction.  It has been 
reported that fetal thyroid function is normal if there is no goiter, but fetal hyperthyroidism or 
hypothyroidism may be suspected if there is thyroid enlargement [14 – 16]. Thus the ultrasound 
became an extremely effective non-invasive tool for detection of fetal thyroid dysfunction. It also 
minimizes the necessity of invasive procedure to diagnose fetal thyroid dysfunction [13]. 
Fetal hypothyroidism is seen in mothers taking antithyroid drugs. Further fetal thyroid status 
evaluation may be obtained from an estimate of bone maturation at the distal femoral center and 
fetal heart rate as well as fetal growth.  
 
Maternal-fetal complications 
 
The complications met in our study were: abortion rate was 5 %.  
15% of pregnant women delivered prematurely. 
Maternal complications were rare (poor weight gain, tachycardia).  
Fetal complications included low birth weight (24%), fetal respiratory distress (10%) 
 
Conclusions 
 
  Close teamwork between obstetricians and endocrinologists minimize fetal and maternal 
risks of Graves’ disease, leading to good prognosis of both of them. 
  First  line  therapy  for  Grave's  disease  during  pregnancy  includes  antithyroid  drugs 
(preferably propylthiouracil). 
  First  line  therapy  for  Grave's  disease  during  pregnancy  includes  antithyroid  drugs 
(preferably propylthiouracil). 
  To asses fetal thyroid function, fetal ultrasound at 28-32 weeks should be performed if there 
is evidence of active maternal Grave’s disease. 
   The improvement in the management of hyperthyroidism in pregnancy, particularly due to 
Graves' disease will depend on: 
-  The capacity of the evaluation of thyroid function during gestation 
-  Further  elucidation  of  the  immunology  of  Graves’  disease  focusing  on  the  TSH 
receptor  and  its  interaction  with  stimulating  antibodies  and  artificial  designer 
compounds, which will provide a rational immunologic therapy.  
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